| Biotechnology Industry | Healthcare Sector | Nicholas Peter Karos CEO | TSX-V Exchange | CA91360F1099 ISIN |
| CA Country | 7 Employees | - Last Dividend | - Last Split | - IPO Date |
Universal Ibogaine Inc. is positioned as a pioneering life sciences entity with a primary focus on the development, acquisition, and operation of addiction treatment clinics across Canada. With its headquarters nestled in Calgary, Canada, the company is engaged in an ambitious endeavor to harness the therapeutic potential of ibogaine, a naturally occurring psychoactive substance, for addressing various forms of addiction. A key facet of its operations involves conducting meticulously planned clinical trials aimed at investigating ibogaine's effectiveness in addiction treatment, thereby contributing to the broader body of research in this domain and potentially revolutionizing how addiction is treated.